Vilven J C, Domalewski M, Prossnitz E R, Ye R D, Muthukumaraswamy N, Harris R B, Freer R J, Sklar L A
Cancer Center and Pathology, University of New Mexico Health Sciences Center, Albuquerque, USA.
J Recept Signal Transduct Res. 1998 Mar-May;18(2-3):187-221. doi: 10.3109/10799899809047744.
Chemoattractant receptors represent a major subset of the G-protein coupled receptor (GPCR) family. One of the best characterized, the N-formyl peptide receptor (FPR), participates in host defense responses of neutrophils. The features of the ligand which regulate its interaction with the FPR are well-known. By manipulating these features we have developed new ligands to probe structural and mechanistic aspects of the peptide-receptor interaction. Three ligand groups have been developed: 1) ligands containing a Lys residue located in positions 2 through 7 that can be conjugated to FITC (N-formyl-Met1-Lys2-Phe3-Phe4, N-formyl-Met1-Leu2-Lys3-Phe4, N-formyl-Met1-Leu2-Phe3-Lys4, N-formyl-Met1-Leu2-Phe3-Phe4-Lys5, N-formyl-nLeu1-Leu2-Phe3-nLeu4-Tyr5-Lys6 and N-formyl-Met1-Leu2-Phe3-Phe4-Gly5-Gly6-Lys7; 2) fluorescent pentapeptide ligands (N-formyl-Met-X-Phe-Phe-Lys(FITC) where X = Leu, Ala, Val or Gly); and 3) small crosslinking ligands where the photoaffinity crosslinker 4-azidosalicylic acid (ASA) was conjugated to Lys in positions 3 and 4 and p-benzoyl-phenylalanine (Bpa) was located in position 2 in N-formyl-Met1-Bpa2-Phe3-Tyr4. The peptides were characterized according to activity and affinity in human neutrophils and cell lines transfected with FPR. All of the peptides were agonists, with parallel affinity and activity. In the first group, the peptide activity decreases as Lys is placed closer to the N-formyl group and the activity is improved by 1-3 orders of magnitude by conjugation with FITC. In the second group, the dissociation rate of the peptide from the receptor increases as position 2 is replaced by aliphatic amino acids with smaller alkyl groups. In the third group, crosslinking ligands remain biologically active, display nM affinity and covalently label the FPR.
趋化因子受体是G蛋白偶联受体(GPCR)家族的一个主要亚类。其中研究最充分的N-甲酰肽受体(FPR)参与中性粒细胞的宿主防御反应。调节其与FPR相互作用的配体特征已为人所知。通过操控这些特征,我们开发了新的配体来探究肽-受体相互作用的结构和机制方面。已开发出三类配体:1)在第2至7位含有赖氨酸残基的配体,其可与异硫氰酸荧光素(FITC)偶联(N-甲酰-Met1-Lys2-Phe3-Phe4、N-甲酰-Met1-Leu2-Lys3-Phe4、N-甲酰-Met1-Leu2-Phe3-Lys4、N-甲酰-Met1-Leu2-Phe3-Phe4-Lys5、N-甲酰-nLeu1-Leu2-Phe3-nLeu4-Tyr5-Lys6和N-甲酰-Met1-Leu2-Phe3-Phe4-Gly5-Gly6-Lys7);2)荧光五肽配体(N-甲酰-Met-X-Phe-Phe-Lys(FITC),其中X = Leu、Ala、Val或Gly);3)小分子交联配体,其中光亲和交联剂4-叠氮基水杨酸(ASA)与第3和4位的赖氨酸偶联,对苯甲酰苯丙氨酸(Bpa)位于N-甲酰-Met1-Bpa2-Phe3-Tyr4的第2位。根据人中性粒细胞和转染FPR的细胞系中的活性和亲和力对这些肽进行了表征。所有这些肽都是激动剂,具有平行的亲和力和活性。在第一组中,随着赖氨酸位置更靠近N-甲酰基,肽活性降低,并且通过与FITC偶联活性提高1至3个数量级。在第二组中,随着第2位被具有较小烷基的脂肪族氨基酸取代,肽从受体的解离速率增加。在第三组中,交联配体保持生物活性,显示出纳摩尔亲和力并共价标记FPR。